Revenue Growth - Revenue increased by 17.9% to RMB 2,124.84 million in the first half of 2024 compared to RMB 1,802.56 million in the same period of 2023[5] - In-hospital solutions revenue increased by 20.2% to RMB 1,688.11 million in the first half of 2024 from RMB 1,404.03 million in the same period of 2023[6] - Out-of-hospital solutions revenue increased by 9.6% to RMB 436.73 million in the first half of 2024 from RMB 398.53 million in the same period of 2023[6] - P2M solutions revenue increased by 67.0% to RMB 107.91 million in the first half of 2024 from RMB 64.61 million in the same period of 2023[6] - Total revenue for the first half of 2024 reached RMB 2,124.8 million, a year-on-year increase of 17.9%[9] - P2M solutions generated total revenue of RMB 107.9 million, with a significant increase of 67.0% compared to the same period in 2023[11] - Revenue from value-added solutions increased by 34.8% to RMB 1,439.3 million[13] - Revenue increased by 17.9% from RMB 1,802.6 million in the first half of 2023 to RMB 2,124.8 million in the first half of 2024, driven by steady growth in both in-hospital and out-of-hospital solutions[22] - In-hospital solutions revenue grew by 20.2% from RMB 1,404.0 million in the first half of 2023 to RMB 1,688.1 million in the first half of 2024, primarily due to increased hospital SaaS penetration and strong growth in P2M solutions[22] - Out-of-hospital solutions revenue increased by 9.6% from RMB 398.5 million in the first half of 2023 to RMB 436.7 million in the first half of 2024, driven by increased SaaS subscriptions and new API sales[22] - Revenue for the six months ended June 30, 2024, was RMB 2,124.8 million, a 17.9% increase from RMB 1,802.6 million in the same period in 2023[68] - Revenue from the "In-Hospital Value-Added Solutions" segment increased to RMB 1,439,278 thousand in 2024 from RMB 1,067,424 thousand in 2023, a growth of 34.8%[87] - Revenue from the "Out-of-Hospital Subscription Solutions" segment rose to RMB 360,295 thousand in 2024 from RMB 297,104 thousand in 2023, an increase of 21.3%[87] - Revenue from the "Patient-to-Manufacturer (P2M)" solutions increased to RMB 107,910 thousand in 2024 from RMB 64,609 thousand in 2023, a significant growth of 67.0%[87] Profitability and Losses - Gross profit decreased by 7.7% to RMB 436.99 million in the first half of 2024 from RMB 473.57 million in the same period of 2023[5] - Operating loss improved by 33.3% to RMB 102.85 million in the first half of 2024 from RMB 154.31 million in the same period of 2023[5] - Net loss improved by 25.5% to RMB 118.94 million in the first half of 2024 from RMB 159.58 million in the same period of 2023[5] - Adjusted net loss (non-IFRS) improved by 44.1% to RMB 32.90 million in the first half of 2024 from RMB 58.86 million in the same period of 2023[5] - Net loss narrowed by 25.5% to RMB 118.9 million, with non-IFRS adjusted net loss narrowing by 44.1% to RMB 32.9 million[9] - Gross margin for P2M solutions decreased by 8.0 percentage points to 74.1%[13] - Gross profit margin decreased from 26.3% in the first half of 2023 to 20.6% in the first half of 2024, mainly due to a shift in revenue mix towards lower-margin solutions[24] - In-hospital solutions gross margin dropped from 30.2% in the first half of 2023 to 21.8% in the first half of 2024, influenced by changes in revenue mix between subscription and value-added solutions[24] - Out-of-hospital solutions gross margin improved from 12.3% in the first half of 2023 to 15.6% in the first half of 2024, driven by higher-quality growth in value-added solutions[24] - Operating loss decreased by 33.3% from RMB 154.3 million in the first half of 2023 to RMB 102.9 million in the first half of 2024, due to stable revenue growth and improved operating leverage[25] - Net loss decreased by 25.5% from RMB 159.6 million in the first half of 2023 to RMB 118.9 million in the first half of 2024, primarily due to revenue growth and operating leverage[27] - Adjusted net loss (non-IFRS measure) decreased to RMB 32.9 million in the first half of 2024 from RMB 58.9 million in the same period of 2023[28] - Adjusted net loss rate (non-IFRS measure) improved to -1.5% in the first half of 2024 from -3.3% in the first half of 2023[29] - Gross profit for the six months ended June 30, 2024, was RMB 437.0 million, a decrease of 7.7% from RMB 473.6 million in the same period in 2023[68] - Operating loss for the six months ended June 30, 2024, was RMB 102.9 million, an improvement from RMB 154.3 million in the same period in 2023[68] - Net loss for the six months ended June 30, 2024, was RMB 118.9 million, compared to RMB 159.6 million in the same period in 2023[68] - Basic and diluted loss per share for the six months ended June 30, 2024, was RMB 0.20, compared to RMB 0.29 in the same period in 2023[68] - The company reported a net loss of RMB 156,002 thousand for the six months ended June 30, 2024[76] - The company's total equity as of June 30, 2024, was RMB 1,724,707 thousand, with a net loss of RMB 115,838 thousand for the six-month period[78] - The company's total comprehensive loss for the six months ended June 30, 2024, was RMB 115,434 thousand, including other comprehensive income of RMB 404 thousand[78] - The company's basic loss per share was RMB 116 million for the six months ended June 30, 2024, compared to RMB 156 million for the same period in 2023[96] Expenses and Costs - Sales and marketing expenses decreased by 15.7% from RMB 454.9 million in the first half of 2023 to RMB 383.6 million in the first half of 2024, reflecting economies of scale and refined expense management[25] - R&D expenses increased slightly from RMB 40.4 million in the first half of 2023 to RMB 41.8 million in the first half of 2024, with the R&D-to-revenue ratio decreasing from 2.0% to 1.7%[25] - Employee costs for the six months ended June 30, 2024, were RMB 280,169 thousand, slightly down from RMB 283,592 thousand in 2023[91] - Government grants decreased to RMB 14,953 thousand in 2024 from RMB 25,068 thousand in 2023[89] - Interest income dropped to RMB 782 thousand in 2024 from RMB 1,226 thousand in 2023[89] - The company's inventory costs increased to RMB 1,663,377 thousand in 2024 from RMB 1,261,046 thousand in 2023, reflecting a 31.9% rise[93] - The company's income tax expense for the six months ended June 30, 2024, was RMB 1,829 thousand, compared to a tax benefit of RMB 1,174 thousand in 2023[94] - The company's inventory sold during the six months ended June 30, 2024, had a book value of RMB 1,663.38 million, up from RMB 1,261.05 million in the same period in 2023[101] - The company's cash outflow for the purchase of property, plant, and equipment and intangible assets was RMB 55,984 thousand for the six months ended June 30, 2024[80] - The company acquired property, plant, and equipment worth RMB 48 million in the six months ended June 30, 2024, compared to RMB 16 million in the same period in 2023[98] Cash Flow and Financial Position - Cash and cash equivalents decreased to RMB 224.2 million as of June 30, 2024, from RMB 243.4 million as of December 31, 2023[31] - Bank and other loans increased to RMB 366.0 million as of June 30, 2024, from RMB 235.0 million as of December 31, 2023[31] - The company's debt-to-asset ratio increased to 36.8% as of June 30, 2024, from 33.2% as of December 31, 2023, primarily due to increased bank loans[35] - Operating cash outflow for the six months ended June 30, 2024, was RMB 195,536 thousand, compared to RMB 54,349 thousand in the same period in 2023[80] - Net cash inflow from financing activities for the six months ended June 30, 2024, was RMB 132,863 thousand, primarily due to bank and other loan proceeds of RMB 257,925 thousand[82] - Cash and cash equivalents decreased by RMB 19,404 thousand to RMB 224,181 thousand as of June 30, 2024, compared to RMB 243,375 thousand at the beginning of the year[82] - The company's capital reserves increased by RMB 236,924 thousand due to the vesting and delivery of restricted share units during the period[78] - Non-controlling interests increased by RMB 3,793 thousand due to the acquisition of a subsidiary during the six-month period[78] - The company's investment activities resulted in a net cash inflow of RMB 43,269 thousand, driven by proceeds from the sale of financial assets at fair value through profit or loss of RMB 96,899 thousand[80] - The company's share-based payment reserve increased by RMB 79,422 thousand due to equity-settled share-based payments during the period[78] - Restricted bank deposits increased to RMB 43,329 thousand as of June 30, 2024, from RMB 23,700 thousand as of December 31, 2023, primarily due to frozen bank deposits[108] - Trade payables decreased to RMB 212,479 thousand as of June 30, 2024, from RMB 233,249 thousand as of December 31, 2023, indicating a reduction in outstanding trade liabilities[109] - Other payables and accrued expenses increased to RMB 391,814 thousand as of June 30, 2024, up from RMB 361,514 thousand as of December 31, 2023, driven by higher flexible workforce payments and other liabilities[111] - The company repurchased 2,282,700 ordinary shares at a cost of RMB 12.7 million under the post-IPO share incentive plan during the six months ended June 30, 2024[115] - Restricted share units (RSUs) granted to employees under the share-based payment plan totaled 8,801,042 shares as of June 30, 2024, compared to 7,765,000 shares in the same period in 2023[120] - The expected credit loss provision for other receivables increased to RMB 13.9 million as of June 30, 2024, from RMB 9.3 million as of December 31, 2023, reflecting higher credit risk assessments[107] - The company's issued and fully paid ordinary shares remained unchanged at 587,038,219 shares as of June 30, 2024, with a total share capital of RMB 391 thousand[114] - The company did not declare or pay any dividends for the six months ended June 30, 2024, consistent with the same period in 2023[112] - The fair value of non-listed equity instruments as of June 30, 2024, was RMB 40,000 thousand, classified under Level 3 valuation[123] - The fair value of wealth management products as of June 30, 2024, was RMB 46,740 thousand, classified under Level 3 valuation[123] - The fair value of fund management products as of June 30, 2024, was RMB 207,340 thousand, classified under Level 3 valuation[123] - A 10% increase/decrease in the fair value of non-listed equity instruments would result in a RMB 4,000,000 increase/decrease in pre-tax profit for the six months ended June 30, 2024[125] - A 0.5% increase/decrease in the weighted average expected return rate would result in a RMB 741,650 decrease/increase in pre-tax loss for the six months ended June 30, 2024[125] Business Expansion and Partnerships - The company is the largest digital chronic disease management solution provider in China based on hospital and pharmacy SaaS deployments and online prescriptions issued through its services as of December 31, 2023[8] - The number of hospitals using Zhiyun Medical SaaS reached 2,732, an increase of 74 hospitals or 2.8% compared to the same period in 2023[12] - The company signed contracts with 41 pharmaceutical companies, a 13.9% increase compared to the same period in 2023[11] - Number of hospitals deploying the company's hospital SaaS increased to 2,732, up 2.8% from 2,658[14] - Number of pharmaceutical companies collaborating on subscription solutions rose to 41, a 13.9% increase from 36[14] - Number of SKUs marketed through digital marketing services grew to 50, up 11.1% from 45[14] - Registered users reached 33.2 million, an 11.8% increase from 29.7 million[18] - Online prescriptions surged to 116.1 million, a 43.9% year-over-year growth[16] - Number of pharmacies using the company's SaaS platform increased to 228,331, covering approximately 35% of pharmacies in China[16] - The company secured an exclusive sub-license for the development and marketing of Iloprost Injection in China, targeting a market with a projected 30% CAGR over the next five years[15] - The company launched Haonuoxin® Sevelamer Carbonate Dry Suspension, addressing patient compliance issues in phosphate binder therapy[20] - The company invested RMB 200 million in Anhui Zhiyi Huiyun Technology Co., Ltd., acquiring a 4.26% stake in the subsidiary[33] - The company acquired 70% equity of Beijing Jiarun Oude Technology Co., Ltd. for RMB 9 million, contributing RMB 19.7 million in revenue and RMB 0.84 million in comprehensive profit for the period ended June 30, 2024[129] - The company entered into a contract to acquire exclusive rights for the manufacture and distribution of pharmaceutical products in China, with a commitment of RMB 178,170 thousand as of June 30, 2024[130] - The company's wholly-owned subsidiary, Hangzhou Zhiyun Huiyi Medical Technology Co., Ltd., was established on December 30, 2020[134] - Chengdu Zhiyun Internet Hospital Co., Ltd., a subsidiary of the company, was registered on June 18, 2021[134] - The consolidated affiliated entities include Hangzhou Kangming, Chengdu Zhiyun Internet Hospital, and Tianjin Zhiyun, whose financial accounts are consolidated under contractual arrangements[134] - The company's global offering includes the Hong Kong public offering and international offering as described in the prospectus[135] - The company's consolidated affiliated entity, Tianjin Zhiyun Comprehensive Clinic Co., Ltd., was established on March 26, 2021[136] Shareholder and Equity Information - Mr. Kuang, a director, holds approximately 23.14% of the company's issued shares, including 135,841,185 shares through controlled entities and direct ownership[54] - Hengtai Trust (Hong Kong) Limited holds 98,624,566 shares, representing approximately 16.80% of the company's issued share capital[58] - Data Vantage Development Limited and HaoYuan Health Limited each hold 94,571,580 shares, representing approximately 16.11% of the company's issued share capital[58] - Jeffrey Steven Yass and related entities collectively hold 31,570,783 shares, representing approximately 5.38% of the company's issued share capital[58] - Global offering proceeds amounted to approximately HKD 425.7 million, with 60% allocated to business expansion, 25% to enhancing medical knowledge and technological capabilities, 5% to strategic partnerships and acquisitions, and 10% to working capital and general corporate purposes[63] - As of June 30, 2024, the company had utilized HKD 70.4 million of the global offering proceeds, leaving HKD 215.1 million unutilized[63] - The company's trustee purchased 2,282,700 shares on the Hong Kong Stock Exchange for a total consideration of approximately RMB 12.7 million during the reporting period[64] - The company's shares are listed on the Main Board of the Hong Kong Stock Exchange[136] - The company's shares have a par value of $0.00001 per share[136] - The company's founder, executive director, chairman, and CEO is Mr. Kuang Ming[135] - The reporting period for the interim report is the six months ended June 30, 2024[136] - The last practicable date for determining certain information in the interim report

上半年业绩稳健增长，经调整净亏损大幅收窄 | --- | --- | --- | |--------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------| | [Table_Rank] 投资评级：买入（维持） | | 主要观点： | | 报告日期： 2024-08-28 | | ⚫[Table_Summary] 事件： | | [Table_BaseData] 收盘价（元） | 1.36 | 2024 年上半年公司收入同比增长 17.9%至 21.25 亿元人民币，非 | | 近 12 个月最高/最低（元） | 6.85/1.30 | 国际财务报告准则(Non-IFRS)调整后净亏损收窄至 3,290 万元，同 | | 总股本（百万股） | 587 | 比大幅收窄 44.1%。 | | 流通股本（百万股） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 截至2024年6月30日止六個月 中期業績公告 智雲健康科技集團（「本公司」，連同其子公司及併表聯屬實體，統稱「本集團」） 董事（「董事」）會（「董事會」）欣然宣佈本集團截至2024年6月30日止六個月（「報 告期」）的未經審核綜合中期業績，連同2023年同期的比較數字。該等中期業績 已經本公司審核委員會審閱。 於本公告內，「我們」及「我們的」指本公司，倘文義另有所指，則指本集團。本 公告所載若干金額及百分比數字經過約整，或者四捨五入至小數點後一位或 兩位。任何表格、圖表或其他地方列出的總數及金額總和之間的任何差異均由 約整造成。 – 1 – 財務摘要 | --- | --- | --- | --- | |------------------------------|---------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][2] Core Views - The introduction of injectable Iloprost solution marks a steady entry into the pulmonary arterial hypertension (PAH) market, which is in urgent need of effective treatment options. The domestic PAH treatment market is expected to grow rapidly in the coming years, with a projected compound annual growth rate (CAGR) of over 30% in the next 3-5 years [1][2] - The global PAH treatment market is anticipated to reach USD 11 billion by 2030, with over 5 million PAH patients in China, highlighting a significant unmet medical need [1][2] - Iloprost is an effective drug for treating PAH, with studies showing it can significantly reduce pulmonary vascular resistance and improve cardiac output. Long-term use can increase the two-year survival rate of patients to 87% [1][2] Financial Summary - Revenue projections for the company are as follows: 2024: CNY 4.827 billion, 2025: CNY 6.129 billion, 2026: CNY 7.728 billion, with year-on-year growth rates of 30.8%, 27.0%, and 26.1% respectively [2][3] - The net profit forecast for the company is as follows: 2024: -CNY 0.4 billion, 2025: CNY 0.03 billion, 2026: CNY 0.66 billion, with adjusted profits of CNY 0.45 billion, CNY 1.5 billion, and CNY 3.4 billion for the respective years [2][3] - The company's operating income for 2023 is CNY 3.691 billion, with a projected increase to CNY 4.827 billion in 2024, and a net profit of -CNY 0.327 billion in 2023, improving to CNY 0.066 billion by 2026 [3][4] Market Position and Strategy - The company effectively connects patients with the pharmaceutical industry through its P2M (Patient to Manufacturer) model, leveraging a nationwide SaaS network and digital capabilities [2][4] - The company is the largest provider of digital chronic disease management solutions in China, focusing on digitizing hospital processes and providing comprehensive lifecycle services for chronic disease patients [1][2]

欢迎各位投资者参加华安医药联合录影中举办的夏季线上策略会本场会议主持人是华安医药首席唐国超老师本场是上市公司智云健康的交流很荣幸能够邀请到了公司领导CFO许总和IR李总来跟我们一起交流我们本场交流主要分为公司介绍和问答环节两个部分首先有请公司领导李总用20到30分钟的时间 对公司的一个新情况最新进展等做一个讲解有请公司领导好的 谢谢怀恩医药的李老师那我们就开始先做公司的介绍 那先跟大家讲一下那均匀健康呢是现在中国最大的这个数字化慢病管理的平台那我们公司业务呢是从2014年就是公司成立然后从2016年正式的开始进入慢病管理这个这个2B的这个行业来开始做的 那大家可以看到这张图呢就主要跟大家展示了我们现在的商业模式其实一句话来概括的话呢就是我们通过了两个SaaS的平台一边是医院的一个医会慢病管理SaaS一个是药店的药店问诊SaaS通过这两个平台呢一边粘住了医院一边粘住了药店也增加了这个整个的医疗就慢病管理相关的参与方的这个粘性提高了整个生态的这个医疗生态的效率 那么我们呢其实从这张图上我们可以这个分板块来讲那首先呢就是我们最大的一个板块是收入占比超过75%以上的就是我们的院内解决方案就是医院相关的这个板块那么 我 ...

欢迎各位投资者参加华安医药联合录影中举办的夏季线上策略会本场会议主持人是华安医药首席唐国超老师本场是上市公司智盈健康的交流很荣幸能够邀请到了公司领导CFO许总和IR李总来跟我们一起交流我们本场交流主要分为公司介绍和问答环节两个部分首先有请公司领导李总用20到30分钟的时间 对公司的一个经营情况最新进展等做一个讲解有请公司领导好的 谢谢怀恩医药的李老师那我们就开始先做公司的介绍 那先跟大家讲一下那志云健康呢是现在中国最大的这个数字化慢病管理的平台那我们公司业务呢是从2014年就是公司成立然后从2016年正式的开始进入慢病管理这个这个2B的这个行业来开始做的 那大家可以看到这张图呢就主要跟大家展示了我们现在的商业模式其实一句话来概括的话呢就是我们通过了两个SaaS的平台一边是医院的一个医会慢病管理SaaS一个是药店的药店问诊SaaS通过这两个平台呢一边粘住了医院一边粘住了药店也增加了这个整个的医疗就慢病管理相关的参与方的这个粘性提高了整个生态的这个医疗生态的效率 那么我们呢其实从这张图上我们可以这个分板块来讲那首先呢就是我们最大的一个板块是收入占比超过75%以上的就是我们的院内解决方案就是医院相关的这个板块那么 ...

智云健康240523华安原文 2024年05月23日11:22 发言人100:01 进入外面管理to b的这个行业来开始做的那大家可以看到这张图就主要跟大家展示了我们现在的商业模 式。其实一句话来概括的话，就是我们通过了两个size的平台。一边先是医院的一个医会慢病管 理sars，一个是药店的药店问诊sars。通过这两个平台，一边粘住了医院，一边粘住了药店，也增加了 整个的医疗慢病管理相关的参与方的年性，提高了整个生态的医疗生态的效率。 发言人100:33 我们其实从这张图上我们可以分板块来讲。首先我们最大的一个板块是收入占比超过75%以上的，就是 我们的院内解决方案，就是医院相关的这个板块。我们我们为什么要来做医院这个事情？其实大家在国 内的话都知道，中国整个的一个医疗，就是以这个公立医院为主导来进行的。所以说，如果你真正的要 去触达这个医疗的核心，你就必须要以医院为先去做这个事。我们从2016年来做这个事情的时候，就意 识到了这一点。所以我们也是一直确立是以医院为先，作为我们的这战略来开展业务的。 发言人101:16 关注公众号/知识星球：股市调研 发言人101:43 在医院端的话，其实首先我们就是要在医 ...

智[T云able健_S康tock（Na 9m 9eR 5p 5tT .y Hpe K] ） 公司研究/公司深度 深耕数字化慢病领域，三大解决方案并行发展 投资评级：买入（首次） 主要观点： [Table_Rank] [T深ab耕le_数S字um化m慢ar病y]领域，逐步迎来收获期 报告日期： 2024-05-13 智云健康科技集团是中国最大的数字化慢病管理解决方案提供 [收Ta盘bl价e_（Ba元se）Data] 3.19 商，2014年在杭州创办，2016年推出中国第一个针对慢病管理 近12个月最高/最低（元） 6.85/2.11 的医院SaaS产品。历经多轮境内外股权融资，公司已初具规模， 总股本（百万股） 587 逐步进入收获期，2023年集团平台注册医生达10.3万人，注册 流通股本（百万股） 587 用户约3,100万人。2019年-2023年，公司营业收入从5.24亿 流通股比例（%） 100% 元增长至36.91亿元，盈利能力呈持续增长态势。 总市值（亿元） 19 2023年3大板块同步发力。 流通市值（亿元） 19  院内解决方案板块：安装SaaS医院数量2,719家,+5.9%YoY； ...

團 ClouDr Group Limited* 智 雲 健 康 ClouDr Group Limited 智雲健康科技集團* 科 技 集 (Incorporated in the Cayman Islands with limited liability) Stock Code : 9955 Annual Report 年報 2023 * For identification purpose only ClouDr Group Limited 智雲健康科技集團* （於開曼群島註冊成立的有限公司） 股份代號 : 9955 年 報 Annual Report 2023 2023 * 僅供識別 目錄 | --- | --- | |--------------------------|-------| | 公司資料 | 2 | | 財務概要 | 4 | | 業務回顧與展望 | 5 | | 管理層討論及分析 | 14 | | 董事會報告 | 21 | | 董事及高級管理層 | 38 | | 其他資料 | 44 | | 企業管治報告 | 53 | | 獨立核數師報告 | 70 | | 綜合損益表 | 75 | | 綜合損 ...

Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 3,690.5 million, representing a year-on-year increase of 23.5%[2] - Gross profit for the same period was RMB 909.4 million, up 14.8% compared to the previous year[2] - The adjusted net loss (non-IFRS) narrowed to RMB 75.1 million, a decrease of 77.4% year-on-year[2] - The company recorded a net loss of approximately RMB 327.3 million for the year ended December 31, 2023, a reduction of 80.7% from RMB 1,692.2 million for the previous year[31] - Operating loss decreased by 46.9% from approximately RMB 591.6 million to approximately RMB 314.2 million, primarily due to significant revenue growth and increased operating leverage[27] - The gross margin for chronic disease management solutions improved to 28.1%, up from 20.7% in 2022[14] - The company incurred a pre-tax loss of RMB 327,326,000 in 2023, a decrease from a loss of RMB 1,693,643,000 in 2022[76] Revenue Breakdown - Revenue from hospital solutions reached RMB 2,873.1 million, reflecting a growth of 31.5%[2] - Revenue from pharmacy solutions reached RMB 658,583,000, a 6.9% increase from RMB 615,812,000 in 2022[11] - Revenue from subscription solutions (precision marketing) revenue decreased by 13.4% to RMB 467.2 million[2] - The newly introduced P2M solutions generated revenue of RMB 101.2 million, as it was not recorded in the previous year[2][3] - Revenue from in-hospital solutions reached RMB 2,873.1 million, a growth of 31.5% from RMB 2,184.5 million in the previous year[8] - Revenue from pharmacy subscription solutions was RMB 59.1 million, a growth of 7.2% from the previous year[10] Strategic Initiatives - The company is focusing on a "patient-to-industry" (P2M) strategy to enhance profitability through strategic partnerships with pharmaceutical companies[4] - The company aims to leverage AI innovations to improve healthcare ecosystem efficiency and enhance digital infrastructure for chronic disease management[4] - The company plans to focus on enhancing its hospital SaaS infrastructure and expanding its self-operated product pipeline under the P2M strategy[18] - The company aims to expand its hospital SaaS network and strengthen relationships with hospitals to enhance commercialization opportunities[6] Operational Metrics - As of December 31, 2023, 2,719 hospitals have installed the company's Zhiyun Yihui SaaS, an increase of 152 hospitals or 5.9% compared to the previous year[9] - The number of pharmaceutical companies contracted for precision marketing services increased by 50.0% to 39 as of December 31, 2023, compared to 26 the previous year[9] - The total number of SKUs in cooperation reached 59, marking a 73.5% increase from 34 SKUs the previous year[9] - The number of pharmacy stores using the Zhiyun Wenjin SaaS reached 219,716, an increase of 26,389 stores or 13.7% from the previous year[10] - The number of registered users for chronic disease management solutions increased to approximately 31.2 million, up 9.5% from 28.5 million in 2022[14] - The total number of full-time employees as of December 31, 2023, was 1,522, with over 3,000 flexible staff supporting business penetration in lower-tier cities[42] Cost and Expenses - Research and development expenses decreased from approximately RMB 114.8 million to approximately RMB 88.0 million, reflecting improved efficiency and reduced R&D requirements for mature products[26] - The ratio of sales and marketing expenses to revenue decreased from 29.2% to 21.5%, indicating improved operational efficiency[24] - The total personnel-related costs for the year ended December 31, 2023, amounted to approximately RMB 1,007.9 million, an increase from RMB 990.3 million for the year ended December 31, 2022[43] - Full-time employee costs for the year ended December 31, 2023, were approximately RMB 629.4 million, compared to RMB 610.2 million for the previous year[43] - Flexible employee costs for the year ended December 31, 2023, were approximately RMB 378.5 million, slightly down from RMB 380.1 million in the previous year[43] Financial Position - Cash and cash equivalents as of December 31, 2023, were approximately RMB 243.4 million, slightly down from RMB 249.7 million in 2022[36] - The debt-to-asset ratio remained stable at 33.2% as of December 31, 2023, compared to 33.6% in 2022[39] - The company’s total equity decreased to RMB 1,765,306 thousand as of December 31, 2023, from RMB 1,881,375 thousand in 2022, a decline of approximately 6.2%[59] - The company’s capital reserves increased significantly due to the proceeds from the share issuance, amounting to approximately RMB 472,020 thousand after deducting issuance expenses[87] Compliance and Governance - The company has complied with all applicable corporate governance codes as of December 31, 2023, with some deviations noted regarding the roles of the Chairman and CEO[46] - The audit committee reviewed the audited consolidated financial statements for the year ended December 31, 2023, and found them compliant with relevant accounting standards[48] - The company has not applied any new standards or interpretations that have not yet come into effect during the accounting period, ensuring compliance with the latest international financial reporting standards[63] Future Outlook - Future growth in chronic disease management solutions is expected to be driven by a favorable business model and increased commercialization efforts[19] - The company plans to meet its working capital needs through cash generated from operations and funds raised from capital markets, with no plans for significant external financing[36]